MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq:GERN) announced today that it will host an analyst and investor meeting in New York City on Tuesday, July 17, 2007. At the meeting, Alan B. Colowick, M.D., M.P.H., president of Oncology, and Fabio Benedetti, M.D., senior vice president of Oncology, Clinical Development, will give an in-depth presentation of Geron’s cancer development programs and clinical trials strategy for GRN163L, the company’s telomerase inhibitor drug, and GRNVAC1, its telomerase cancer vaccine. A question-and-answer session and discussion will follow the formal presentation.
